IDH1 and IDH2 Mutation Analysis, Exon 4, Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue
2014188
Ordering Recommendation
IDH1/IDH2 mutational status is a prognostic marker in individuals with low- and high-grade gliomas. Aid in distinguishing a primary from a secondary glioblastoma.
Mnemonic
IDH1-2FFPE
Methodology
Polymerase Chain Reaction/Sequencing
Performed
Sun, Tue, Thu
Reported
8-14 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
- Patient Preparation
- Collect
- Tumor tissue. Also acceptable: DNA extracted by CLIA certified lab with corresponding client-circled H&E slide.
- Specimen Preparation
- Tumor Tissue: Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Tissue block will be returned after testing.Transport tissue block or 4 unstained 5-micron slides. (Min: 3 slides) Transport block and/or slide(s) in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect™or contact ARUP Client Services at (800) 522-2787.
Extracted DNA: Transport 40 uL DNA with at least 50 ng/uL concentration. (Min: 40 uL) Transport DNA in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. - Storage/Transport Temperature
- Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
Extracted DNA: Refrigerated. - Unacceptable Conditions
- Less than 25 percent tumor. DNA extracted by a non-CLIA lab. DNA extracted without a corresponding circled H&E slide. Specimens fixed/processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). Decalcified specimens.
- Remarks
- For FFPE specimens include surgical pathology report.
- Stability
- Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Extracted DNA Ambient: 1 month; Refrigerated: Indefinitely; Frozen: Indefinitely
Reference Interval
Interpretive Data
Refer to report.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
Hotline History
View Hotline History
CPT Code(s)
88381; 81120; 81121
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2002148 | Block ID | 57723-9 |
| 2006445 | IDH1 and IDH2 Mutation Results | 35474-6 |
| 2014216 | IDH1-2 FFPE Source |
Aliases
- IDH1
- IDH1 SNP
- IDH2
- Isocitrate dehydrogenase (IDH) 1 and 2
- Isocitrate Dehydrogenase 1
- Isocitrate Dehydrogenase 2
- NADP+